E
ITCI

Ergoteles’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Ergoteles’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,842
Closed -$479K – 1611
2023
Q1 		$479K Buy
+8,842
New +$428K 0.02% 747
2022
Q4 		– Sell
-15,742
Closed -$732K – 1971
2022
Q3 		$732K Buy
15,742
+12,175
+341% +$636K 0.03% 618
2022
Q2 		$204K Buy
+3,567
New +$202K 0.01% 1316
2022
Q1 		– Sell
-53,656
Closed -$2.81M – 1697
2021
Q4 		$2.81M Buy
53,656
+42,256
+371% +$1.78M 0.11% 200
2021
Q3 		$425K Buy
+11,400
New +$396K 0.02% 651
2021
Q1 		– Sell
-14,500
Closed -$461K – 1116
2020
Q4 		$461K Buy
+14,500
New +$381K 0.02% 470

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ergoteles's ITCI Position: Q2 2023 in Review

Ergoteles sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 8,842 shares — an estimated $479K sold.

Ergoteles first reported a position in ITCI in Q4 2020 and held it in 6 quarters. The position peaked at $2.81M in Q4 2021. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Ergoteles reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Ergoteles sold 8,842 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $479K.
  • Ergoteles first reported a position in Intra-Cellular Therapies Inc. in Q4 2020 and held it in 6 quarters.
  • Ergoteles's Intra-Cellular Therapies Inc. position peaked at $2.81M in Q4 2021.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Ergoteles's 13F filing for Q2 2023, filed 14 Aug 2023.